A 70-year-old male with a history of diabetes, hyperlipidaemia and hypertension managed with atenolol presented to his family physician with lower urinary tract symptoms (LUTS). He was prescribed terazosin. Over the course of a year he noticed worsening erectile dysfunction (ED) with difficulty maintaining a hard erection until orgasm.
Elderly patients on androgen deprivation therapy (ADT) as part of prostate cancer treatment may be at an increased risk of depression, a recent study states.
Salvage radical prostatectomy (SRP) after radiation produces good long-term survival rates in men with prostate adenocarcinoma, according to a recent study.
The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.
Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.
Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.
Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.
Targeted antibiotic prophylaxis – after a rectal swab to identify specific intestinal flora – does not appear to significantly impact the risk of urinary sepsis following a transrectal ultrasound (TRUS)-guided prostate biopsy, according to a recent study.